Alterations in the expression of PDCD4 in ductal carcinoma of the breast - PubMed (original) (raw)
. 2007 Dec;18(6):1387-93.
Affiliations
- PMID: 17982621
Alterations in the expression of PDCD4 in ductal carcinoma of the breast
Yong Hannah Wen et al. Oncol Rep. 2007 Dec.
Abstract
Programmed cell death 4 gene (PDCD4), an in vivo repressor of transformation, was originally isolated from a human glioma library by screening it with an antibody against a nuclear antigen in proliferating cells. PDCD4 functions as a transformation repressor by inhibiting the activity of the RNA helicase, eIF4A. We previously showed that retinoids, anti-estrogens and HER2/neu antagonist induce PDCD4 expression in human breast cancer cell lines. Very little is known about the expression of PDCD4 in human breast cancer tissues or the significance of the PDCD4 expression in breast cancer. To gain insight into the pattern of the PDCD4 expression in breast tissues, we performed an immunohistochemical analysis of the PDCD4 expression in 80 archived, normal and ductal breast carcinoma tissues (invasive and carcinoma in situ) (DCIS) and correlated PDCD4 expression with expression of known prognostic markers in breast cancer (ER, PR and HER2/neu). To assess the role of methylation on PDCD4 expression in breast cancer cells, breast cancer cell lines were treated with the demethylating agent 5-deoxy-azacytidine and analyzed for PDCD4 expression. We observed primarily nuclear localization of PDCD4 in ductal carcinoma in situ compared to normal breast tissues where the PDCD4 expression was predominantly cytoplasmic. This was seen more frequently in DCIS cases that were ER positive and HER2/neu negative samples. PDCD4 expression was markedly decreased in the invasive ductal carcinoma. We did not observe any significant relationship between PDCD4 expression and the expression of RAR or PR. In T-47D, MDA-MB-435 and MDA-MB-231 cells, treatment with 5-deoxy-azacytidine did not result in an increased expression of PDCD4. The present study demonstrated altered cellular localization of PDCD4 when comparing normal breast to neoplastic breast tissues. In addition, there was a decreased expression of PDCD4 in breast cancer when compared with normal breast tissue. A loss of the PDCD4 expression in breast cancer cell lines does not appear to result from hypermethylation of the PDCD4 promoter.
Similar articles
- Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Afonja O, et al. Oncogene. 2004 Oct 21;23(49):8135-45. doi: 10.1038/sj.onc.1207983. Oncogene. 2004. PMID: 15361828 - Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Half E, et al. Cancer Res. 2002 Mar 15;62(6):1676-81. Cancer Res. 2002. PMID: 11912139 - Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
Biswas DK, Iglehart JD. Biswas DK, et al. J Cell Physiol. 2006 Dec;209(3):645-52. doi: 10.1002/jcp.20785. J Cell Physiol. 2006. PMID: 17001676 Review. - Small cell carcinoma of the breast.
Mirza IA, Shahab N. Mirza IA, et al. Semin Oncol. 2007 Feb;34(1):64-6. doi: 10.1053/j.seminoncol.2006.10.029. Semin Oncol. 2007. PMID: 17270668 Review.
Cited by
- eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model.
González-Ortiz A, Pulido-Capiz A, Castañeda-Sánchez CY, Ibarra-López E, Galindo-Hernández O, Calderón-Fernández MA, López-Cossio LY, Díaz-Molina R, Chimal-Vega B, Serafín-Higuera N, Córdova-Guerrero I, García-González V. González-Ortiz A, et al. Cells. 2022 Dec 15;11(24):4069. doi: 10.3390/cells11244069. Cells. 2022. PMID: 36552834 Free PMC article. - Induction of premature senescence and a less-fibrogenic phenotype by programmed cell death 4 knockdown in the human hepatic stellate cell line Lieming Xu-2.
Perveen R, Ozaki I, Manirujjaman M, Mine K, Murata Y, Tanaka K, Xia J, Takahashi H, Anzai K, Matsuhashi S. Perveen R, et al. Hum Cell. 2023 Mar;36(2):583-601. doi: 10.1007/s13577-022-00844-9. Epub 2022 Dec 16. Hum Cell. 2023. PMID: 36522523 Free PMC article. - Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis.
Nguyen THN, Nguyen TTN, Nguyen TTM, Nguyen LHM, Huynh LH, Phan HN, Nguyen HT. Nguyen THN, et al. Breast Cancer Res Treat. 2022 Nov;196(1):1-15. doi: 10.1007/s10549-022-06728-8. Epub 2022 Sep 9. Breast Cancer Res Treat. 2022. PMID: 36085533 Review. - The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract.
Ferris WF. Ferris WF. Front Oncol. 2022 Jun 29;12:903374. doi: 10.3389/fonc.2022.903374. eCollection 2022. Front Oncol. 2022. PMID: 35847932 Free PMC article. Review. - Dissecting the Roles of PDCD4 in Breast Cancer.
Cai Q, Yang HS, Li YC, Zhu J. Cai Q, et al. Front Oncol. 2022 Jun 20;12:855807. doi: 10.3389/fonc.2022.855807. eCollection 2022. Front Oncol. 2022. PMID: 35795053 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous